BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / Metabolic

...comprising ATB200 and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....
BioCentury | Nov 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

...a rhGAA, and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....
BioCentury | Jul 18, 2015
Company News

Management tracks

...uniQure N.V. (NASDAQ:QURE) hired Charles Richard as SVP of neuroscience R&D. Richard was CMO at Oxyrane U.K. Ltd....
BioCentury | Jan 21, 2013
Company News

Oxyrane management update

Oxyrane U.K. Ltd. , Manchester, U.K. Business: Endocrine/Metabolic Hired: Susan Flint as executive director and head of clinical operations, formerly program director at Navidea Biopharmaceuticals Inc. ; and Charles Richard as CMO, formerly principal medical director...
BioCentury | Dec 13, 2012
Distillery Techniques

Technology: Drug platforms

...heart and thigh muscle of glycogen better than unmodified GAA. Next steps carried out by Oxyrane U.K. Ltd....
...Nat. Biotechnol.; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...
BioCentury | Dec 13, 2012
Targets & Mechanisms

Muscling up on Myozyme

...from Sanofi . 1,2 BioMarin has moved its therapy into a Phase I/II trial, whereas Oxyrane...
...to long infusion times and adverse reactions, including fever, tachycardia, cyanosis and hypotension. 4 Thus, Oxyrane...
...Biotechnol. ; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...
BioCentury | Dec 12, 2011
Product Development

Muscling in on Myozyme

...Phase III trials. Some of those reactions were severe, including fever, tachycardia, cyanosis and hypotension. Oxyrane...
...enzyme would have a potential value advantage over Myozyme," said Sander Slootweg, a director at Oxyrane...
...investor New Science Ventures in Oxyrane's $26.5 million series D round. To increase cellular uptake, Oxyrane...
BioCentury | Nov 21, 2011
Financial News

Oxyrane completes venture financing

Oxyrane U.K. Ltd. , Manchester, U.K. Business: Endocrine/Metabolic Date completed: 11/17/11 Type: Venture financing Raised: $26.5 million Investors: Forbion Capital Partners; Morningside Group; New Science Ventures WIR Staff...
BioCentury | Nov 18, 2011
Financial News

Oxyrane raises $26.5M in a series D

...round. New investors Forbion Capital Partners and Morningside Group joined existing investor New Science Ventures. Oxyrane...
...for greater efficacy at lower product doses. Forbion's Sander Slootweg and Morningside's Gerald Chan joined Oxyrane's...
Items per page:
1 - 9 of 9
BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / Metabolic

...comprising ATB200 and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....
BioCentury | Nov 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

...a rhGAA, and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....
BioCentury | Jul 18, 2015
Company News

Management tracks

...uniQure N.V. (NASDAQ:QURE) hired Charles Richard as SVP of neuroscience R&D. Richard was CMO at Oxyrane U.K. Ltd....
BioCentury | Jan 21, 2013
Company News

Oxyrane management update

Oxyrane U.K. Ltd. , Manchester, U.K. Business: Endocrine/Metabolic Hired: Susan Flint as executive director and head of clinical operations, formerly program director at Navidea Biopharmaceuticals Inc. ; and Charles Richard as CMO, formerly principal medical director...
BioCentury | Dec 13, 2012
Distillery Techniques

Technology: Drug platforms

...heart and thigh muscle of glycogen better than unmodified GAA. Next steps carried out by Oxyrane U.K. Ltd....
...Nat. Biotechnol.; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...
BioCentury | Dec 13, 2012
Targets & Mechanisms

Muscling up on Myozyme

...from Sanofi . 1,2 BioMarin has moved its therapy into a Phase I/II trial, whereas Oxyrane...
...to long infusion times and adverse reactions, including fever, tachycardia, cyanosis and hypotension. 4 Thus, Oxyrane...
...Biotechnol. ; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...
BioCentury | Dec 12, 2011
Product Development

Muscling in on Myozyme

...Phase III trials. Some of those reactions were severe, including fever, tachycardia, cyanosis and hypotension. Oxyrane...
...enzyme would have a potential value advantage over Myozyme," said Sander Slootweg, a director at Oxyrane...
...investor New Science Ventures in Oxyrane's $26.5 million series D round. To increase cellular uptake, Oxyrane...
BioCentury | Nov 21, 2011
Financial News

Oxyrane completes venture financing

Oxyrane U.K. Ltd. , Manchester, U.K. Business: Endocrine/Metabolic Date completed: 11/17/11 Type: Venture financing Raised: $26.5 million Investors: Forbion Capital Partners; Morningside Group; New Science Ventures WIR Staff...
BioCentury | Nov 18, 2011
Financial News

Oxyrane raises $26.5M in a series D

...round. New investors Forbion Capital Partners and Morningside Group joined existing investor New Science Ventures. Oxyrane...
...for greater efficacy at lower product doses. Forbion's Sander Slootweg and Morningside's Gerald Chan joined Oxyrane's...
Items per page:
1 - 9 of 9